Click below to register.


Nikko Hotel

222 Mason St
San Francisco, CA

Room: Nikko Ballrooms I & II

Registration and Dinner 6:15 PM – 6:45 PM
Interactive CME Symposium 6:45 PM – 8:15 PM

This activity is supported by an educational grant from Bristol-Myers Squibb.

Immune checkpoint inhibitor (ICI) therapies are revolutionizing survival outcomes for patients with advanced/metastatic (A/M) renal cell carcinoma (RCC) and urothelial carcinoma of the bladder (UCB) who do not respond to previous therapies. ICI therapies act by suppressing the T-cell checkpoint pathways that tumors use to evade immune detection. The development of ICIs has been fast and furious, with important variations among the agents in indications, role of biomarkers in optimizing patient selection and therapeutic outcomes, possible role as multimodal therapy, treatment response, and manifestation of immune-related adverse events. This interactive symposium will feature discussions of clinical cases of A/M RCC and UCB cancers to highlight the most up-to-date and rapidly emerging data on these agents and discuss some of the important but not well known characteristics of ICI therapy as these agents become part of the standard of care.

The goal of this program is to provide healthcare practitioners on the interdisciplinary GU cancer team, in both academic and community settings, with the most up-to-date information on shifting treatment paradigms and optimal treatment strategies with immune checkpoint inhibitors for metastatic and advanced renal cell carcinoma and urothelial carcinoma of the bladder.

After completing this activity, the participant should be better able to:
  • EVALUATE the clinical value of immune checkpoint inhibitors (ICIs) in the treatment of advanced/metastatic (A/M) renal cell carcinoma (RCC) and urothelial carcinoma of the bladder (UCB), through an improved understanding of their unique mechanism of action and clinical evidence for their use.
  • REVIEW the latest literature on predictive biomarkers to inform optimal patient selection for mono- and combination-ICI therapy, particularly in bladder and kidney cancers.
  • IMPLEMENT novel emerging approaches to mitigate immune-related adverse events in A/M RCC & UCB patients.
  • DEVELOP individualized evidence-based immunotherapy treatment plans for A/M RCC & UCB.
Physician Accreditation Statement - This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and ASiM CE LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

*This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation - Global Education Group designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education - Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.50 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Welcome, Overview & Introduction of Patient Cases
Nizar M. Tannir, MD, FACP

The Role of Immune Checkpoint Inhibitors (ICIs) in Advanced/Metastatic Renal Cell Carcinoma
Nizar M. Tannir, MD, FACP

The Role of ICIs in Urothelial Carcinoma of the Bladder
Arjun V. Balar, MD

Novel Approaches to the Management of immune-related Adverse Events with ICIs
Nizar M. Tannir, MD, FACP

Review of Cases and Discussion/Q&A
Nizar M. Tannir, MD, FACP, and Arjun V. Balar, MD

This schedule is subject to change.

tannirR_webNizar M. Tannir, MD, FACP (Course Director)
Professor and Deputy Chair
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

balar_R_webArjun V. Balar, MD
Associate Professor of Medicine
Director of the Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

The educational design of this activity addresses the needs of medical oncologists in academic and community settings, urologists, post-doctoral fellows, advanced practitioners (NPs, PAs, PharmDs), and all others on the interdisciplinary GU cancer team involved in the treatment of patients with RCC and UCB.

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Americans with Disabilities Act (ADA)
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Cathy Zehr prior to the live event at 908-253-9001, ext 15.

For information about the accreditation of this program, please contact Global at 303-395-1782 or

There is no fee for this educational activity.

Submit a case to review at meeting:

<img src="" alt="procced to pretest" border="0" />

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us